mRNA

Covid-19
#Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna submits initial data to FDA for Covid-19 vaccine booster 

Moderna has initiated its submission to the US Food and Drug Administration (FDA) for the evaluation of a booster dose of the Moderna Covid-19 vaccine (mRNA-1273) at the 50 µg dose level. The company expects to submit data to the European Medicines Agency (EMA) and other regulatory authorities around the world… Read More

#News

Covid-19
#Clinical trials #Covid-19 #Immunotherapy #Moderna #mRNA #Pfizer

Study on third Covid-19 vaccine dose in kidney transplant recipients 

A pilot study has begun to assess the antibody response to a third dose of an authorised Covid-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech Covid-19 vaccine. The Phase II trial is sponsored and funded by the National Institute of Allergy and… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Third Covid-19 vaccine approved for immunocompromised

Moderna has announced that the U.S. Food and Drug Administration (FDA) has approved an update to the emergency use authorisation for the Moderna Covid-19 vaccine (mRNA-1273) to include a third dose for immunocompromised individuals. The third dose will available to people 18 years of age or older in the United… Read More

#Covid-19 #News

#Biotherapeutics #Clinical trial #mRNA #Therapeutics

Positive interim results from Phase I study for sickle cell disease treatment

Massachusetts-headquartered Fulcrum Therapeutics has announced positive interim results from the ongoing single and multiple-ascending dose (SAD and MAD) Phase I trial with FTX-6058 in healthy adult volunteers. FTX-6058 is an investigational, potent and selective small molecule inhibitor of EED designed to increase the expression of fetal hemoglobin (HbF) with the… Read More

#News #Trending News

#Biologics #Cancer research #Drug development #mRNA #R&D

What it means for drug discovery to partner with a CDMO

Following the announcement by Samsung Biologics that it planned to add mRNA vaccine drug substance manufacturing services to its offering, DDW’s Megan Thomas spoke to Seahee Kim about what this means for both business and drug development.   MT: As a CDMO, Samsung Biologics can offer both development and manufacturing services. Read More

#Business & Investment #Cancer Research #Editor's Choice #Exclusive Content #News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #mRNA #Novel therapeutics #Oncology #Research

This week in drug discovery (2-6 August)

News round-up by DDW’s Megan Thomas for 2-6 August This week has seen results released, research continued, and clinical trial phases completed. DDW’s Megan Thomas has rounded up her top five stories showing promise in the drug discovery industry. Cardiac patients receiving nasal gel showed reduction of S. aureus… Read More

#News #Trending News

#Drug development #Immunology / Virology & Vaccines #mRNA #Therapeutics

Sanofi to acquire Translate Bio

Sanofi has acquired Translate Bio as part of its endeavour to accelerate the application of mRNA to develop therapeutics and vaccines. Under the agreement, Sanofi will acquire all outstanding shares for a total equity value of approximately $3.2 billion (on a fully diluted basis). “Translate Bio adds an mRNA technology… Read More

#News #Trending News

#Clinical trials #Covid-19 #Moderna #mRNA #Therapeutics

Moderna doses first patient with its IL-2 mRNA therapeutic candidate

Moderna has dosed the first patients in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2, modified for the expansion of regulatory T cells. mRNA-6231 is Moderna’s first autoimmune candidate to enter the clinic and its first subcutaneously administered therapeutic program. “The initiation of the Phase I study of… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #mRNA #Pfizer #Vaccines

The human touch: the benefits of real world evidence

Listen to this article on the DDW Podcast: Lu Rahman looks at the growing role of real world evidence and its benefits in the fight against Covid-19. Real world evidence (RWE)  is nothing new. While clinical trials have a significant part to play  - and indeed remain the ultimate standard for… Read More

#Business & Investment #Covid-19 #Editor's Choice #Exclusive Content #News

#Covid-19 #Drug development #Drug discovery #mRNA

Can antiviral oligonucleotides better prepare us for the next pandemic?

Todd Stawicki, Global Marketing Manager for MS Biopharma at SCIEX, offers an in-depth analysis of oligonucleotides and their role in preparing for the next pandemic Covid-19, the disease caused by SARS-CoV-2, is arguably the greatest public health threat in a generation. It has temporarily paralysed our just-in-time economy1,2 and highlighted many… Read More

#Exclusive Content #News

#Drug delivery #Drug development #mRNA #Pfizer

Pfizer’s investment that will help speed up new medicine development

Around 85% of Pfizer's small molecule products pass through Sandwich, Kent, on their journey to market. The work of the Kent site’s team helps millions of patients globally. Brian Henry, Vice President, Drug Product Design, Medicinal Sciences provides Megan Thomas, Drug Discovery World with insight into the scientific learnings of… Read More

#Exclusive Content #News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Sanofi launches dedicated mRNA vaccines centre

Sanofi will invest approximately €400 million annually in a vaccines mRNA Centre of Excellence. The centre will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams… Read More

#News

#Drug development #Gene therapy #mRNA #Therapeutics

Evonik to develop new drug delivery platform for mRNA

Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). Starting in June 2021, Evonik and Stanford scientists begin a three-year sponsored research collaboration to develop the polymer-based drug delivery system, which Evonik will license… Read More

#News

#Clinical trial #Clinical Trial Authorisation #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna initiates rolling submission of Biologics License Application (BLA)

Moderna has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older. Stéphane Bancel, Chief Executive Officer of Moderna, said: “We look forward… Read More

#News #Trending News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Samsung Biologics adds mRNA vaccine manufacturing to its services

Samsung Biologics, a CDMO, plans to add mRNA vaccine drug substance (DS) manufacturing capability to its current facility in Songdo, ready for cGMP operations within early 2022. mRNA has been the technology of choice for many Covid-19 vaccines due to its characteristics of safety and fast scalability in manufacturing. “We… Read More

#News